PTAB challenges

Proceedings overview

There is one AIA trial proceeding on file for US Patent 12096974. This proceeding resulted in a discretionary denial of institution, which means the patent claims were not challenged on the merits and remain sustained. This gives a defendant a stronger defensive posture as the patent has survived an initial challenge.

IPR2025-01127 — Aerin Medical Inc. v. Neurent Medical Ltd

• Type: Inter Partes Review
• Filed: 2025-06-27
• Status: Discretionary Denial — The PTAB declined to institute the IPR.
• Judge panel: Not publicly available at this stage of the proceeding.
• Petition grounds: Not publicly available as the petition was not instituted.
• Institution decision: Denied — 2025-12-23. The status indicates a "Discretionary Denial," which means the Board exercised its discretion under 35 U.S.C. § 314(a) or § 324(a) to not institute the inter partes review.
• Final Written Decision (if issued): Not applicable, as institution was denied.
• Settlement / termination: Not applicable, as institution was denied.
• Appeal: Not applicable, as institution was denied.
• Defensive value: The patent owner, Neurent Medical Ltd, prevailed at the institution stage, meaning the claims of US12096974 were not reviewed on their merits. This indicates a stronger position for the patent owner, and an IPR-based defense will be harder given the patent has already overcome one attempt at institution.

Strategic summary

All claims of US Patent 12096974 remain untested by AIA trial proceedings. The single IPR filed, IPR2025-01127, was denied institution on discretionary grounds, meaning the merits of the patentability challenge were not reached. Therefore, no claims have been canceled or invalidated through PTAB proceedings, and all claims are considered sustained in this context.

The estoppel landscape remains largely open for other potential petitioners. Since IPR2025-01127 was denied institution on discretionary grounds, rather than on the merits of the prior art presented, it is less likely to trigger the full scope of estoppel under 35 U.S.C. § 315(e)(2) for Aerin Medical Inc. (the petitioner) or their privies compared to a scenario where institution was granted and a final written decision was issued. This implies that many prior-art grounds may still be available for future challenges by other parties.

This proceeding does not signal a pattern of aggressive PTAB appeals by the patent owner, as the case did not proceed to a final written decision. The petitioner, Aerin Medical Inc., appears to be a defensive aggregator, having previously filed petitions against other patents.

Recommended next steps

For a potential defendant, while the patent has survived one IPR attempt, no claims have been adjudicated on the merits. Therefore, a thorough prior art search and analysis is still warranted if considering an IPR challenge. The discretionary denial in IPR2025-01127 indicates that the PTAB may be exercising its discretion to manage its docket or based on specific procedural aspects of the petition, rather than a strong indication of patentability. If considering a new IPR, carefully consider the PTAB's discretionary factors outlined in Fintiv and subsequent guidance.

The status of IPR2025-01127 can be monitored on the USPTO PTAB E2E system.